| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.03. | Roche Inaugurates Research Facility for the Institute of Human Biology | ||
| 23.03. | GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate | ||
| 23.03. | Viatris' Effexor Approved in Japan for Generalized Anxiety Disorder | ||
| 23.03. | Cambrex Advances U.S. and European Expansions | ||
| 20.03. | AstraZeneca to Invest in Shanghai Innovation Center | ||
| 20.03. | Novartis Agrees to Acquire Pan-Mutant-Selective PI3KA Inhibitor from Synnovation Therapeutics | ||
| 19.03. | Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases | ||
| 19.03. | SK pharmteco Makes $100M Funding Commitment to Support Viral Vector Business | ||
| 19.03. | Roche Enters Academic-Industry Collaboration with NIPER Raebareli in India | ||
| 19.03. | Evotec Receives Milestone Payment from BMS for Protein Degradation Collaboration | ||
| 19.03. | Esteve CDMO to Add New Production Unit in Celr | ||
| 19.03. | Phlow Corp. Taps Dawn Von Rohr as Chief Operating Officer | ||
| 19.03. | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer | ||
| 19.03. | LGM Pharma Commits an Additional $9M to its Texas and Colorado Facilities | ||
| 18.03. | Kupando Secures €10M More in Series A Funding for Oncology, Infectious Disease Programs | ||
| 18.03. | Excalipoint Therapeutics Launches, Will Develop Next-Gen T-Cell Engagers | ||
| 18.03. | Samsung Bioepis, Sandoz Ink Licensing Agreement for Up to Five Biosimilars | ||
| 18.03. | Oxford Biomedica Signs Licensing Deal with Australia's VVMF | ||
| 18.03. | Green Elephant Biotech Introduces Archimedes One for Cell Therapy Manufacturing | ||
| 18.03. | IsomAb Appoints Dr. Philip Brainin as Chief Executive Officer | ||
| 18.03. | Aptamer Group Introduces Targeted Radiopharmaceutical Program | ||
| 17.03. | Terumo BCT, Taiwan Bio to Advance Treg Manufacturing onto Automated Platform | ||
| 17.03. | Axplora Expands Farmabios Site in Gropello Cairoli | ||
| 17.03. | SK pharmteco Completes Regulatory Inspection of La Porte Facility | ||
| 17.03. | Alchemab Appoints Ulrich Wendt as Chief Business Officer |